|
(V894) |
Fat distribution and sarcopenia affect morbidity and mortality in patients undergoing transcatheter aortic valve replacement |
|
|
B. Niemann, O. Uluocak, J. Marieke, F. Knapp, I. Oswald, R. Schulz, A. Böning, H. Nef, G. Krombach, S. Rohrbach (Gießen) |
|
|
Diskussion |
|
(V895) |
Clinical Outcome Following Transcatheter Aortic Valve Implantation in Patients With Chronic Obstructive Pulmonary Disease |
|
|
P. Doldi, J. Steffen, M. Zadrozny, L. Stolz, J. Gmeiner, T. Stocker, M. Orban, H. D. Theiss, K. Rizas, N. Kneidinger, S. Sadoni, J. Buech, C. Hagl, S. Massberg, J. Hausleiter, S. Deseive, D. Braun (München) |
|
|
Diskussion |
|
(V896) |
Temporal trends of TAVI treatment characteristics in high volume centers in Germany 2013 – 2020 |
|
|
V. Mauri, M. Abdel-Wahab, S. Bleiziffer, V. Veulemans, A. Sedaghat, M. Adam, G. Nickenig, M. Kelm, H. Thiele, S. Baldus, T. K. Rudolph (Köln, Leipzig, Bad Oeynhausen, Düsseldorf, Bonn) |
|
|
Diskussion |
|
(V897) |
Prognostic relevance of residual mitral and tricuspid regurgitation after transcatheter aortic valve implantation (TAVI): impact of follow-up time-point for decision making |
|
|
M. Franz, L. Baez, K. Ibrahim, S. Möbius-Winkler, M. Diab, T. Kräplin, C. Schulze (Jena, Chemnitz) |
|
|
Diskussion |
|
(V898) |
Systematisches Amyloidose-Screening bei Patienten mit Aortenklappenstenose |
|
|
K. Wrede-Wihl, S. Sömken, F. Knebel, B. Pieske, K. Hahn, D. Messroghli, I. Mattig (Berlin) |
|
|
Diskussion |
|
(V899) |
Transcatheter aortic valve replacement before and after the COVID-19 related implementation of a patient triage concept Patient triage for TAVR during COVID-19 |
|
|
N. Berisha, K. Klein, V. Veulemans, O. Maier, K. Piayda, S. N. Binnebößel, S. S. Afzal, A. Polzin, R. Westenfeld, P. Horn, C. Jung, M. Kelm, T. Zeus (Dusseldorf, Düsseldorf) |
|
|
Diskussion |